Medtronic concludes enrollment in 'extreme risk' study of CoreValve
Medtronic ($MDT) has wrapped up patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The study is enrolling more than 1,500 patients in 45 sites, with approximately two-thirds of patients in the high-risk study. The system is designed to replace diseased aortic valves without open-heart surgery. Medtronic release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: